Research programme: inflammation therapy - AstraZeneca

Drug Profile

Research programme: inflammation therapy - AstraZeneca

Latest Information Update: 15 Feb 2008

Price : $50

At a glance

  • Originator AstraZeneca; Cambridge Antibody Technology
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 15 Feb 2008 This programme is available for partnering (
  • 15 Feb 2008 Research is ongoing in Respiratory disorders and Inflammation
  • 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top